| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 19 | 2020 | 188 | 4.750 |
Why?
|
| Marijuana Smoking | 16 | 2020 | 39 | 4.290 |
Why?
|
| Alcohol Drinking | 27 | 2024 | 260 | 3.720 |
Why?
|
| Urban Population | 12 | 2019 | 97 | 3.310 |
Why?
|
| African Americans | 16 | 2022 | 1435 | 3.080 |
Why?
|
| Adolescent | 88 | 2024 | 3799 | 2.700 |
Why?
|
| Young Adult | 71 | 2024 | 2825 | 2.570 |
Why?
|
| Diabetes Mellitus, Type 1 | 16 | 2024 | 274 | 2.320 |
Why?
|
| Cannabis | 8 | 2024 | 29 | 2.260 |
Why?
|
| HIV Infections | 8 | 2024 | 429 | 2.200 |
Why?
|
| Adolescent Behavior | 12 | 2020 | 64 | 2.090 |
Why?
|
| Risk-Taking | 9 | 2019 | 97 | 1.820 |
Why?
|
| Female | 126 | 2024 | 21490 | 1.810 |
Why?
|
| Alcohol-Related Disorders | 6 | 2022 | 21 | 1.790 |
Why?
|
| Male | 119 | 2024 | 20697 | 1.770 |
Why?
|
| Emigrants and Immigrants | 7 | 2020 | 248 | 1.720 |
Why?
|
| Humans | 155 | 2024 | 34474 | 1.700 |
Why?
|
| Students | 19 | 2022 | 178 | 1.690 |
Why?
|
| Smoking | 18 | 2023 | 544 | 1.440 |
Why?
|
| Substance-Related Disorders | 8 | 2024 | 140 | 1.410 |
Why?
|
| Marijuana Abuse | 7 | 2023 | 20 | 1.390 |
Why?
|
| Universities | 20 | 2022 | 152 | 1.350 |
Why?
|
| Adult | 70 | 2024 | 10015 | 1.280 |
Why?
|
| Poverty | 8 | 2019 | 118 | 1.220 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2024 | 47 | 1.160 |
Why?
|
| Hispanic Americans | 10 | 2019 | 948 | 1.130 |
Why?
|
| Longitudinal Studies | 24 | 2023 | 801 | 1.120 |
Why?
|
| Social Environment | 6 | 2019 | 82 | 1.100 |
Why?
|
| Tobacco Use Disorder | 5 | 2023 | 90 | 1.090 |
Why?
|
| Alcoholism | 7 | 2024 | 103 | 1.070 |
Why?
|
| Marketing | 3 | 2024 | 41 | 1.050 |
Why?
|
| Alcoholic Intoxication | 5 | 2014 | 28 | 1.000 |
Why?
|
| United States | 34 | 2024 | 4267 | 0.990 |
Why?
|
| Cross-Sectional Studies | 27 | 2024 | 1607 | 0.990 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 69 | 0.960 |
Why?
|
| Child | 29 | 2023 | 2613 | 0.890 |
Why?
|
| Mood Disorders | 5 | 2022 | 22 | 0.870 |
Why?
|
| Baltimore | 9 | 2020 | 50 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 1523 | 0.730 |
Why?
|
| Risk Factors | 28 | 2023 | 4136 | 0.720 |
Why?
|
| Cocaine | 5 | 2023 | 355 | 0.710 |
Why?
|
| Logistic Models | 15 | 2019 | 808 | 0.700 |
Why?
|
| Social Support | 5 | 2024 | 195 | 0.680 |
Why?
|
| Homosexuality, Male | 4 | 2024 | 105 | 0.680 |
Why?
|
| Multifactorial Inheritance | 3 | 2023 | 24 | 0.670 |
Why?
|
| Cohort Studies | 13 | 2024 | 1910 | 0.650 |
Why?
|
| Product Labeling | 4 | 2021 | 19 | 0.640 |
Why?
|
| Cluster Analysis | 6 | 2016 | 128 | 0.640 |
Why?
|
| Preventive Health Services | 1 | 2020 | 39 | 0.630 |
Why?
|
| Minority Groups | 3 | 2019 | 90 | 0.630 |
Why?
|
| Mental Disorders | 6 | 2014 | 127 | 0.630 |
Why?
|
| North Carolina | 29 | 2020 | 1612 | 0.610 |
Why?
|
| Social Problems | 1 | 2019 | 2 | 0.600 |
Why?
|
| European Continental Ancestry Group | 4 | 2018 | 1176 | 0.570 |
Why?
|
| Depression | 6 | 2016 | 458 | 0.560 |
Why?
|
| Peer Group | 5 | 2020 | 45 | 0.500 |
Why?
|
| Mothers | 4 | 2018 | 94 | 0.500 |
Why?
|
| Mammography | 6 | 2006 | 43 | 0.480 |
Why?
|
| Commerce | 5 | 2024 | 70 | 0.460 |
Why?
|
| Age Factors | 10 | 2016 | 1261 | 0.460 |
Why?
|
| Social Behavior | 4 | 2019 | 74 | 0.460 |
Why?
|
| Mass Screening | 4 | 2019 | 268 | 0.460 |
Why?
|
| Postmenopause | 7 | 2006 | 461 | 0.450 |
Why?
|
| Hypoglycemia | 3 | 2024 | 45 | 0.420 |
Why?
|
| Diabetic Ketoacidosis | 4 | 2024 | 12 | 0.420 |
Why?
|
| Breast | 5 | 2005 | 68 | 0.410 |
Why?
|
| Socioeconomic Factors | 8 | 2024 | 446 | 0.400 |
Why?
|
| Estrogen Replacement Therapy | 9 | 2006 | 222 | 0.400 |
Why?
|
| Prevalence | 12 | 2024 | 1034 | 0.400 |
Why?
|
| Health Promotion | 4 | 2023 | 264 | 0.390 |
Why?
|
| Mental Health | 2 | 2024 | 126 | 0.390 |
Why?
|
| Models, Statistical | 6 | 2015 | 193 | 0.380 |
Why?
|
| Receptors, Dopamine | 1 | 2012 | 26 | 0.370 |
Why?
|
| Putamen | 1 | 2012 | 28 | 0.360 |
Why?
|
| Social Dominance | 1 | 2012 | 24 | 0.360 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 29 | 0.360 |
Why?
|
| Sexual Behavior | 6 | 2024 | 129 | 0.360 |
Why?
|
| Blood Glucose | 5 | 2022 | 529 | 0.360 |
Why?
|
| Prospective Studies | 12 | 2024 | 2461 | 0.350 |
Why?
|
| Program Development | 1 | 2012 | 98 | 0.350 |
Why?
|
| Comorbidity | 8 | 2019 | 596 | 0.350 |
Why?
|
| Censuses | 1 | 2011 | 10 | 0.340 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 112 | 0.340 |
Why?
|
| Middle Aged | 29 | 2024 | 12703 | 0.340 |
Why?
|
| Educational Status | 6 | 2018 | 185 | 0.340 |
Why?
|
| Insulin | 4 | 2022 | 394 | 0.330 |
Why?
|
| Tobacco | 3 | 2021 | 58 | 0.330 |
Why?
|
| Suicide, Attempted | 7 | 2009 | 33 | 0.320 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 555 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 364 | 0.300 |
Why?
|
| Virginia | 11 | 2018 | 63 | 0.300 |
Why?
|
| Sex Factors | 5 | 2016 | 707 | 0.300 |
Why?
|
| Diabetes Complications | 3 | 2019 | 189 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2006 | 42 | 0.290 |
Why?
|
| Violence | 2 | 2019 | 18 | 0.270 |
Why?
|
| Parents | 3 | 2023 | 159 | 0.260 |
Why?
|
| Crime | 2 | 2019 | 7 | 0.250 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2006 | 15 | 0.250 |
Why?
|
| Depressive Disorder | 4 | 2017 | 76 | 0.240 |
Why?
|
| Odds Ratio | 4 | 2021 | 480 | 0.240 |
Why?
|
| Stress, Psychological | 2 | 2018 | 233 | 0.240 |
Why?
|
| Food Supply | 5 | 2024 | 68 | 0.240 |
Why?
|
| Minors | 1 | 2005 | 6 | 0.240 |
Why?
|
| Estrogens, Conjugated (USP) | 6 | 2006 | 159 | 0.240 |
Why?
|
| Staphylococcal Infections | 5 | 2007 | 83 | 0.240 |
Why?
|
| Medroxyprogesterone Acetate | 7 | 2006 | 115 | 0.230 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 367 | 0.230 |
Why?
|
| Legislation, Drug | 2 | 2019 | 7 | 0.230 |
Why?
|
| Staphylococcus aureus | 4 | 2007 | 58 | 0.230 |
Why?
|
| Cocaine-Related Disorders | 2 | 2007 | 125 | 0.230 |
Why?
|
| Models, Theoretical | 1 | 2006 | 145 | 0.230 |
Why?
|
| Unsafe Sex | 2 | 2017 | 23 | 0.230 |
Why?
|
| Focus Groups | 3 | 2021 | 125 | 0.220 |
Why?
|
| Flavoring Agents | 1 | 2024 | 5 | 0.210 |
Why?
|
| Age of Onset | 3 | 2018 | 95 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2012 | 38 | 0.210 |
Why?
|
| Mental Health Services | 2 | 2003 | 36 | 0.210 |
Why?
|
| South Carolina | 1 | 2024 | 31 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 21 | 0.210 |
Why?
|
| Health Surveys | 4 | 2019 | 202 | 0.210 |
Why?
|
| Hormones | 1 | 2024 | 26 | 0.210 |
Why?
|
| Carrier State | 5 | 2007 | 23 | 0.200 |
Why?
|
| Progestins | 2 | 2006 | 27 | 0.200 |
Why?
|
| Self Concept | 2 | 2013 | 47 | 0.190 |
Why?
|
| Air Microbiology | 4 | 2007 | 19 | 0.190 |
Why?
|
| Cannabidiol | 1 | 2022 | 8 | 0.190 |
Why?
|
| Dyslexia | 3 | 2007 | 8 | 0.180 |
Why?
|
| Hallucinogens | 1 | 2022 | 12 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 4 | 2019 | 79 | 0.180 |
Why?
|
| Models, Psychological | 2 | 2005 | 28 | 0.180 |
Why?
|
| Cognition | 2 | 2023 | 576 | 0.180 |
Why?
|
| Ethnic Groups | 4 | 2021 | 483 | 0.180 |
Why?
|
| Sexual Partners | 2 | 2019 | 37 | 0.180 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 260 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 265 | 0.170 |
Why?
|
| Family Characteristics | 3 | 2023 | 39 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 4 | 2007 | 123 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 61 | 0.170 |
Why?
|
| Alcoholic Beverages | 1 | 2020 | 6 | 0.160 |
Why?
|
| Biometry | 2 | 2000 | 14 | 0.160 |
Why?
|
| Employment | 3 | 2016 | 52 | 0.160 |
Why?
|
| Managed Care Programs | 1 | 2000 | 43 | 0.160 |
Why?
|
| Geography | 2 | 2011 | 36 | 0.160 |
Why?
|
| Parent-Child Relations | 2 | 2016 | 48 | 0.160 |
Why?
|
| Heroin | 1 | 2020 | 33 | 0.160 |
Why?
|
| Progesterone | 4 | 2005 | 112 | 0.160 |
Why?
|
| Data Collection | 5 | 2013 | 191 | 0.160 |
Why?
|
| Infant Behavior | 2 | 2016 | 9 | 0.160 |
Why?
|
| Health Status | 2 | 2020 | 411 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 122 | 0.150 |
Why?
|
| Common Cold | 4 | 2007 | 11 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 168 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 94 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2023 | 755 | 0.150 |
Why?
|
| Law Enforcement | 2 | 2020 | 27 | 0.150 |
Why?
|
| Sex Education | 1 | 2019 | 3 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2022 | 365 | 0.150 |
Why?
|
| Interviews as Topic | 3 | 2015 | 272 | 0.150 |
Why?
|
| Perception | 1 | 2019 | 107 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 145 | 0.140 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 19 | 0.140 |
Why?
|
| Product Packaging | 1 | 2018 | 9 | 0.140 |
Why?
|
| Women, Working | 1 | 2018 | 12 | 0.140 |
Why?
|
| Community-Based Participatory Research | 3 | 2017 | 122 | 0.140 |
Why?
|
| Self Administration | 3 | 2023 | 385 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 177 | 0.140 |
Why?
|
| Registries | 1 | 2019 | 328 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2018 | 47 | 0.140 |
Why?
|
| Nasal Mucosa | 4 | 2006 | 17 | 0.140 |
Why?
|
| Quality of Life | 6 | 2019 | 1032 | 0.140 |
Why?
|
| Body Weight | 1 | 2019 | 343 | 0.140 |
Why?
|
| Psychometrics | 3 | 2016 | 143 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 2366 | 0.130 |
Why?
|
| Self Efficacy | 2 | 2018 | 79 | 0.130 |
Why?
|
| Smoking Cessation | 3 | 2015 | 216 | 0.130 |
Why?
|
| Genotype | 1 | 2019 | 743 | 0.130 |
Why?
|
| Condoms | 1 | 2017 | 34 | 0.130 |
Why?
|
| Adiposity | 1 | 2018 | 204 | 0.130 |
Why?
|
| Social Facilitation | 2 | 2007 | 2 | 0.130 |
Why?
|
| Macaca fascicularis | 2 | 2023 | 548 | 0.120 |
Why?
|
| Urban Health | 1 | 2016 | 15 | 0.120 |
Why?
|
| Tobacco, Smokeless | 1 | 2015 | 16 | 0.120 |
Why?
|
| Sexuality | 1 | 2015 | 14 | 0.110 |
Why?
|
| Internet | 4 | 2024 | 207 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 1998 | 390 | 0.110 |
Why?
|
| Student Health Services | 1 | 2014 | 6 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 170 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 42 | 0.110 |
Why?
|
| Hospitalization | 6 | 2006 | 500 | 0.110 |
Why?
|
| Bone Density | 2 | 2006 | 208 | 0.110 |
Why?
|
| Counseling | 1 | 2014 | 99 | 0.110 |
Why?
|
| Life Change Events | 2 | 2021 | 21 | 0.100 |
Why?
|
| Aggression | 2 | 2019 | 31 | 0.100 |
Why?
|
| Health Personnel | 1 | 2015 | 131 | 0.100 |
Why?
|
| Rural Population | 2 | 2014 | 297 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2006 | 310 | 0.100 |
Why?
|
| Child Abuse | 1 | 2013 | 28 | 0.100 |
Why?
|
| Friends | 1 | 2012 | 8 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2012 | 26 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 508 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 59 | 0.090 |
Why?
|
| Homovanillic Acid | 1 | 2012 | 15 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 50 | 0.090 |
Why?
|
| Menstrual Cycle | 1 | 2012 | 68 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 85 | 0.090 |
Why?
|
| Inflammation | 2 | 2006 | 557 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 84 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 129 | 0.090 |
Why?
|
| Restaurants | 1 | 2011 | 10 | 0.090 |
Why?
|
| Ascorbic Acid | 2 | 2023 | 21 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 176 | 0.080 |
Why?
|
| Animals | 6 | 2023 | 8544 | 0.080 |
Why?
|
| C-Reactive Protein | 3 | 2006 | 248 | 0.080 |
Why?
|
| Central Nervous System Depressants | 1 | 2011 | 63 | 0.080 |
Why?
|
| Aged | 13 | 2019 | 10998 | 0.080 |
Why?
|
| Aging | 4 | 2002 | 1010 | 0.080 |
Why?
|
| Depressive Disorder, Major | 2 | 2001 | 41 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 583 | 0.080 |
Why?
|
| Electroconvulsive Therapy | 2 | 2001 | 30 | 0.080 |
Why?
|
| Statistics as Topic | 3 | 2006 | 111 | 0.080 |
Why?
|
| Protective Clothing | 2 | 2007 | 27 | 0.080 |
Why?
|
| Attention | 2 | 2021 | 91 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2005 | 96 | 0.080 |
Why?
|
| Population | 1 | 2009 | 8 | 0.080 |
Why?
|
| Phenotype | 2 | 2023 | 656 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2011 | 378 | 0.080 |
Why?
|
| Anxiety Disorders | 2 | 2007 | 81 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 803 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2006 | 35 | 0.070 |
Why?
|
| Family | 1 | 2009 | 123 | 0.070 |
Why?
|
| Ethanol | 1 | 2011 | 198 | 0.070 |
Why?
|
| Child Development | 1 | 2009 | 47 | 0.070 |
Why?
|
| Rhinovirus | 2 | 2005 | 9 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 819 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2005 | 597 | 0.070 |
Why?
|
| Estrone | 2 | 2006 | 13 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2019 | 1354 | 0.070 |
Why?
|
| Time Factors | 5 | 2018 | 2352 | 0.070 |
Why?
|
| Sample Size | 1 | 2007 | 40 | 0.070 |
Why?
|
| Psychosocial Deprivation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2007 | 3 | 0.070 |
Why?
|
| Social Identification | 1 | 2007 | 8 | 0.060 |
Why?
|
| Fluorenes | 1 | 2007 | 4 | 0.060 |
Why?
|
| Research Design | 2 | 2007 | 337 | 0.060 |
Why?
|
| Likelihood Functions | 2 | 2014 | 52 | 0.060 |
Why?
|
| Parenting | 1 | 2007 | 24 | 0.060 |
Why?
|
| Discrimination Learning | 1 | 2007 | 20 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2006 | 565 | 0.060 |
Why?
|
| Phobic Disorders | 1 | 2007 | 10 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2007 | 33 | 0.060 |
Why?
|
| Student Dropouts | 1 | 2006 | 5 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2007 | 31 | 0.060 |
Why?
|
| Exercise | 2 | 2023 | 700 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 25 | 0.060 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2007 | 33 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2007 | 32 | 0.060 |
Why?
|
| Piperazines | 1 | 2007 | 64 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 23 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2006 | 40 | 0.060 |
Why?
|
| Reinforcement Schedule | 1 | 2007 | 103 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2006 | 18 | 0.060 |
Why?
|
| Problem-Based Learning | 1 | 2006 | 29 | 0.060 |
Why?
|
| Crack Cocaine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Schools | 1 | 2006 | 67 | 0.060 |
Why?
|
| Incidence | 2 | 2023 | 1288 | 0.060 |
Why?
|
| Conditioning, Operant | 1 | 2007 | 125 | 0.060 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 922 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 73 | 0.060 |
Why?
|
| Forecasting | 3 | 2020 | 153 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2005 | 45 | 0.060 |
Why?
|
| Estradiol Congeners | 1 | 2005 | 3 | 0.060 |
Why?
|
| Culture | 1 | 2005 | 41 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2007 | 147 | 0.060 |
Why?
|
| Testosterone | 1 | 2005 | 51 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 49 | 0.060 |
Why?
|
| Child Behavior Disorders | 1 | 2005 | 12 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2007 | 303 | 0.060 |
Why?
|
| Anxiety | 1 | 2006 | 206 | 0.060 |
Why?
|
| Cough | 2 | 2020 | 21 | 0.060 |
Why?
|
| Air Pollutants | 1 | 2005 | 27 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 193 | 0.060 |
Why?
|
| California | 2 | 2022 | 68 | 0.060 |
Why?
|
| Patient Dropouts | 2 | 2002 | 28 | 0.060 |
Why?
|
| Students, Medical | 1 | 2006 | 136 | 0.050 |
Why?
|
| Mexico | 2 | 2015 | 72 | 0.050 |
Why?
|
| Picornaviridae Infections | 1 | 2004 | 4 | 0.050 |
Why?
|
| Utilization Review | 2 | 2003 | 19 | 0.050 |
Why?
|
| Taste | 1 | 2024 | 18 | 0.050 |
Why?
|
| Child Behavior | 1 | 2004 | 27 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 163 | 0.050 |
Why?
|
| Gender Identity | 1 | 2024 | 28 | 0.050 |
Why?
|
| Staphylococcus | 1 | 2004 | 10 | 0.050 |
Why?
|
| Religion | 2 | 2014 | 31 | 0.050 |
Why?
|
| Cross Infection | 1 | 2004 | 62 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4150 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2023 | 21 | 0.050 |
Why?
|
| Magnesium | 1 | 2023 | 30 | 0.050 |
Why?
|
| Sodium | 1 | 2023 | 42 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 1122 | 0.050 |
Why?
|
| Adolescent Health Services | 1 | 2003 | 12 | 0.050 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 61 | 0.050 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2023 | 26 | 0.050 |
Why?
|
| Aftercare | 1 | 2003 | 35 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 46 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2001 | 267 | 0.050 |
Why?
|
| Insulin Infusion Systems | 1 | 2022 | 7 | 0.050 |
Why?
|
| Eating | 1 | 2023 | 81 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 75 | 0.050 |
Why?
|
| Headache | 2 | 2020 | 78 | 0.050 |
Why?
|
| Smoke | 1 | 2022 | 16 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2023 | 88 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 49 | 0.050 |
Why?
|
| Estrogens | 2 | 2004 | 210 | 0.040 |
Why?
|
| Telecommunications | 1 | 2001 | 7 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 343 | 0.040 |
Why?
|
| Behavior | 1 | 2001 | 31 | 0.040 |
Why?
|
| Problem Solving | 1 | 2001 | 29 | 0.040 |
Why?
|
| Employer Health Costs | 1 | 2000 | 2 | 0.040 |
Why?
|
| Adolescent Development | 1 | 2020 | 3 | 0.040 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2000 | 4 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2000 | 16 | 0.040 |
Why?
|
| Emotions | 1 | 2021 | 60 | 0.040 |
Why?
|
| Patient Admission | 1 | 2001 | 59 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 633 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2015 | 194 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 418 | 0.040 |
Why?
|
| Interleukin-6 | 3 | 2006 | 257 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 200 | 0.040 |
Why?
|
| Outpatients | 1 | 2000 | 61 | 0.040 |
Why?
|
| Antisocial Personality Disorder | 1 | 2020 | 2 | 0.040 |
Why?
|
| Demography | 3 | 2009 | 112 | 0.040 |
Why?
|
| Dizziness | 1 | 2020 | 9 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2000 | 101 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 53 | 0.040 |
Why?
|
| Mental Recall | 1 | 2020 | 52 | 0.040 |
Why?
|
| Maryland | 1 | 2019 | 28 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2001 | 250 | 0.040 |
Why?
|
| Inpatients | 1 | 2000 | 88 | 0.040 |
Why?
|
| Memory | 2 | 1998 | 216 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 36 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2019 | 11 | 0.040 |
Why?
|
| Social Perception | 1 | 2019 | 25 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2000 | 55 | 0.040 |
Why?
|
| Iontophoresis | 1 | 1999 | 7 | 0.040 |
Why?
|
| Bisexuality | 1 | 2019 | 32 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 924 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2000 | 149 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 1999 | 75 | 0.040 |
Why?
|
| Achilles Tendon | 1 | 1999 | 26 | 0.040 |
Why?
|
| beta Carotene | 1 | 1998 | 6 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1999 | 52 | 0.040 |
Why?
|
| Vitamin E | 1 | 1998 | 20 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2018 | 28 | 0.040 |
Why?
|
| Adolescent, Hospitalized | 1 | 1998 | 2 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 703 | 0.040 |
Why?
|
| Placebos | 1 | 1998 | 69 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 67 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1999 | 104 | 0.040 |
Why?
|
| Social Class | 1 | 2018 | 94 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 1998 | 72 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 246 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 245 | 0.030 |
Why?
|
| Antioxidants | 1 | 1998 | 126 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 1603 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 168 | 0.030 |
Why?
|
| Sneezing | 2 | 2007 | 8 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 1998 | 197 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2018 | 245 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2007 | 26 | 0.030 |
Why?
|
| Dementia | 1 | 1998 | 252 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2007 | 355 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2004 | 934 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 211 | 0.030 |
Why?
|
| Public Policy | 1 | 2015 | 34 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 2015 | 31 | 0.030 |
Why?
|
| State Government | 1 | 2014 | 33 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2014 | 82 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2015 | 55 | 0.030 |
Why?
|
| Tobacco Industry | 1 | 2014 | 25 | 0.030 |
Why?
|
| Acculturation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Personality | 1 | 2014 | 15 | 0.030 |
Why?
|
| Linear Models | 2 | 2006 | 464 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 11 | 0.030 |
Why?
|
| Progesterone Congeners | 2 | 2004 | 22 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2014 | 161 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 212 | 0.020 |
Why?
|
| Patient Discharge | 2 | 2006 | 214 | 0.020 |
Why?
|
| Affect | 2 | 2001 | 72 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 3812 | 0.020 |
Why?
|
| Geriatric Assessment | 2 | 2001 | 369 | 0.020 |
Why?
|
| Communicable Disease Control | 1 | 2007 | 14 | 0.020 |
Why?
|
| Particulate Matter | 1 | 2007 | 32 | 0.020 |
Why?
|
| Haloperidol | 1 | 2007 | 15 | 0.020 |
Why?
|
| Quinpirole | 1 | 2007 | 16 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2006 | 5 | 0.020 |
Why?
|
| Intention | 1 | 2006 | 31 | 0.020 |
Why?
|
| Empathy | 1 | 2006 | 17 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2006 | 46 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2007 | 82 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 43 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2005 | 3 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2005 | 34 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 265 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2006 | 135 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 96 | 0.010 |
Why?
|
| Curriculum | 1 | 2006 | 217 | 0.010 |
Why?
|
| Coagulase | 1 | 2004 | 3 | 0.010 |
Why?
|
| Ribotyping | 1 | 2004 | 3 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 19 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 24 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2004 | 47 | 0.010 |
Why?
|
| Hospitals, Psychiatric | 1 | 2003 | 2 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 325 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 222 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1118 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 953 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 306 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 509 | 0.010 |
Why?
|
| Walking | 1 | 2002 | 217 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 150 | 0.010 |
Why?
|
| Arthritis | 1 | 2000 | 43 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1946 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1999 | 57 | 0.010 |
Why?
|
| Neurobehavioral Manifestations | 1 | 1998 | 1 | 0.010 |
Why?
|
| Colorado | 1 | 1998 | 43 | 0.010 |
Why?
|
| Vasomotor System | 1 | 1998 | 25 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 231 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 120 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 612 | 0.010 |
Why?
|
| Weight Gain | 1 | 1998 | 117 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 318 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1209 | 0.010 |
Why?
|
| Patient Selection | 1 | 1999 | 291 | 0.010 |
Why?
|
| Recurrence | 1 | 1998 | 295 | 0.010 |
Why?
|
| Women's Health | 1 | 1998 | 242 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 493 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1999 | 1506 | 0.010 |
Why?
|
| Hypertension | 1 | 2000 | 1024 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2001 | 3618 | 0.010 |
Why?
|